Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 6/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30379965 | 1.00 | ADRA2C (0.58) | ADRA2CADRA1AHRH3GLSMAPT | |
| SCHEMBL24183570 | 0.88 | ADRA2C (0.74) | ADRA2CADRA1AHRH3 | |
| SCHEMBL29787281 | 0.88 | ADRA2C (0.74) | ADRA2CADRA1AHRH3 | |
| SCHEMBL29787296 | 0.87 | ADRA2C (0.73) | ADRA2CADRA1AHRH3ACKR3 | |
| SCHEMBL24183626 | 0.87 | ADRA2C (0.73) | ADRA2CADRA1AHRH3ACKR3 | |
| SCHEMBL24183596 | 0.86 | ADRA2C (0.56) | ADRA2CADRA1AHRH3ACKR3 | |
| SCHEMBL30359186 | 0.85 | ADRA2C (0.57) | ADRA2CADRA1AHRH3ACKR3 | |
| SCHEMBL24183620 | 0.85 | ADRA2C (0.57) | ADRA2CADRA1AHRH3ACKR3 | |
| SCHEMBL24183660 | 0.85 | ADRA2C (0.57) | ADRA2CADRA1AHRH3ACKR3 | |
| SCHEMBL30379971 | 0.85 | ADRA2C (0.57) | ADRA2CADRA1AHRH3ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230115270-A1 | INHIBITORS OF ADRENORECEPTOR ADRAC2 | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2022008426-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2022-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230115270-A1 | INHIBITORS OF ADRENORECEPTOR ADRAC2 | ADRA2C, ADRB2, ADRB3 | ADRA2C 1/4885ADRA1A 17/4885HRH3 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.